Source: International Congress 2017 – Bronchial asthma management
Disease area: Airway diseases



Rating:

Share or cite this content

Citations should be made in the following way:
N. Gunsoy (London, United Kingdom). Impact of mepolizumab on work productivity and activity impairment in severe eosinophilic asthma. 654

Member's Comments

No comment yet.

Related content which might interest you: Mepolizumab improves activity limitation in severe eosinophilic asthma Source: International Congress 2017 – Notable abstracts in asthma Year: 2017 Real-life treatment of severe eosinophilic asthma with mepolizumab Source: International Congress 2019 – Real-world experience of monoclonal antibodies in asthma Year: 2019 Clinical response to mepolizumab in patients with severe eosinophilic asthma Source: International Congress 2019 – Understanding, monitoring and targeting severe asthma Year: 2019 Improvement in rhinosinusitis health related quality of life in patients with severe eosinophilic asthma Source: International Congress 2017 – Management of asthma in different situations Year: 2017 Anti-IL5 therapy could prevent lung function decline in severe eosinophilic asthma: data from the belgian severe asthma registry Source: Virtual Congress 2021 – Clinical features and new biomarkers of asthma, COPD and chronic cough Year: 2021 Continued long-term mepolizumab in severe eosinophilic asthma protects from asthma worsening versus stopping mepolizumab: COMET trial Source: Virtual Congress 2020 – Recent innovations regarding the mechanisms and treatments of asthma Year: 2020 Mepolizumab in real-life treatment of severe eosinophilic asthma Source: Virtual Congress 2020 – Monoclonal antibodies in asthma Year: 2020 Omalizumab treatment reduces asthma exacerbations in children with moderate or severe persistent asthma Source: International Congress 2017 – Paediatric asthma: treatment modalities and behavioural issues Year: 2017 Mepolizumab efficacy in patients with severe eosinophilic asthma and bronchiectasis Source: International Congress 2019 – Real-world experience of monoclonal antibodies in asthma Year: 2019 The characteristics of treatment failure with omalizumab in patients with severe asthma: The impact of eosinophilic complication Source: Virtual Congress 2020 – Monoclonal antibodies in asthma Year: 2020 Impact of omalizumab in patients with severe asthma Source: Annual Congress 2009 - Aspects of uncontrolled asthma Year: 2009 Late Breaking Abstract - The impact of treatment with mepolizumab on airway remodeling in patients with severe eosinophilic asthma. Source: Virtual Congress 2021 – Asthma clinical trials and real-life studies Year: 2021 Real-life experience with mepolizumab in the French early access program for severe eosinophilic asthma Source: International Congress 2019 – Treatment of asthma with monoclonal antibodies Year: 2019 Late Breaking Abstract - Daily physical activity in patients with severe eosinophilic asthma and the effect of anti-IL5 therapy. Source: International Congress 2018 – New pharmacological strategies in airway diseases Year: 2018 Mepolizumab improves small airway function in severe eosinophilic asthma Source: International Congress 2018 – The value of lung function testing in various pathophysiological conditions Year: 2018 Are a degree of asthma therapy related to asthma control impairment? Source: Eur Respir J 2003; 22: Suppl. 45, 370s Year: 2003 Rapid Benralizumab effectiveness in patients with severe eosinophilic asthma and bronchiectasis Source: Virtual Congress 2020 – Monoclonal antibodies in asthma Year: 2020 Daily physical activity and lung function decline in adult-onset asthma Source: International Congress 2017 – Respiratory and exercise physiology Year: 2017 Effects of omalizumab on markers of eosinophilic inflammation in patients with severe allergic asthma Source: Annual Congress 2011 - Biomarkers and exacerbations of asthma and COPD Year: 2011 Both moderate and severe exacerbations accelerate physical activity decline in COPD patients Source: Eur Respir J, 51 (1) 1702110; 10.1183/13993003.02110-2017 Year: 2018